Table 2 Clinical patient characteristics
|  | Pediatric HSCT recipients (n = 16) |
|---|---|
Transplant-related characteristics | |
Age at time of HSCT, years | 7.2 ± 5.3 |
Time after HSCT, years | 14.8 ± 5.0 |
Malignant disorder, n (%) | 10 (62.5%) |
 ALL or AML | 8 |
 MDS or CML | 2 |
Non-malignant disorder, n (%) | 6 (37.5%) |
 Hematological disease | 4 |
 Other | 2 |
Anthracycline therapy, n (%) | 7 (43.8%) |
 < 300 mg/m2 | 5 |
 ≥ 300 mg/m2 | 2 |
Radiotherapy, n (%) | 8 (50.0%) |
 Total body irradiation | 7 |
 Chest irradiation | 1 |
Cyclophosphamide therapy, n (%) | 14 (87.6%) |
 < 1 g/m2 | 1 |
 ≥ 1 g/m2 | 13 |
Allogeneic HSCT, n (%) | 15 (94%) |
 HLA-identical sibling | 6 |
 Other related or unrelated donor | 9 |
Graft versus host disease, n (%) | 5 (31.3%) |
 Acute | 2 |
 Chronic | 3 |
Clinical parameters | |
 Systolic blood pressure, mmHg | 121 ± 12 |
 Diastolic blood pressure, mmHg | 76 ± 9 |
 Pulse, beats per minute | 75 ± 12 |